Canaccord Genuity Reiterates a 'Buy' on Amarin Corporation (AMRN); NFR Reaction is Overdone
Tweet
Share
E-mail
Get Alerts AMRN Hot Sheet
Price: $13.97 -0.71%
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $25.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on commercial, partnership potential of AMR101. We think AMR101, Amarin’s 96 p potential of AMR101. % EPA omega-3 for high triglycerides, will be approved for hypertriglyceridemia on its July 26 PDUFA data and expect IP and business development progress in H2/12."
"We think NFR prior art baseline triglyceride (TG) claims argument is weak. The NFR includes a number of new prior art references to establish close and overlapping baseline TGs with those claimed in ‘408 and ‘889. We note overlap occurs on the high end of the prior art range of a single study and do not believe prior art high TG sub-analysis was done."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $7.92 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on commercial, partnership potential of AMR101. We think AMR101, Amarin’s 96 p potential of AMR101. % EPA omega-3 for high triglycerides, will be approved for hypertriglyceridemia on its July 26 PDUFA data and expect IP and business development progress in H2/12."
"We think NFR prior art baseline triglyceride (TG) claims argument is weak. The NFR includes a number of new prior art references to establish close and overlapping baseline TGs with those claimed in ‘408 and ‘889. We note overlap occurs on the high end of the prior art range of a single study and do not believe prior art high TG sub-analysis was done."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $7.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin presents REDUCE-IT legacy analysis at ESC Congress 2026
- Rubrik Inc (RBRK) PT Raised to $115 at BMO Capital
- Best Buy (BBY) PT Raised to $95 at DA Davidson Following Earnings
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
